T he docking of WPB in endothelial cells has been shown to be mediated in much the same manner that occurs with the docking and exocytosis of neurotransmitters, which includes the formation of soluble N-ethylmaleimide-sensitive factor (NSF) attachment protein receptor (SNARE) complexes on vesicles as they approach the plasma membrane. In conjunction with NSF, SNAREs bind WPB as they approach the endothelial cell plasma membrane. However, it is the effector a-soluble NSF attachment protein (aSNAP) that permits the fusion of WPB to the membrane to occur. 3 In the end, each hexameric NSF requires 3 aSNAPs to mediate binding to the SNAREs. 4 There is evidence of G-protein-coupled receptor involvement in aSNAP/SNARE complex formation (eg, Zhao et al 5 ), but not in the vasculature and not in knockout mice. Overall, this intricate molecular process allows for specific targeting, and the dynamics permit the docking to occur rapidly as the cellular environment changes.
What Rusu et al demonstrate is that aSNAP is regulated by Ga12 in both unstimulated and stimulated (with thrombin, activating protease-activated receptor [PAR]) conditions ( Figure 1 ). This was initially demonstrated using Ga12 2/2 mice and double-knockout mice in which Ga11 was deleted throughout the animal and Gaq was deleted only in the endothelium (EC-Gaq 2/2 ;Ga11 2/2 ). During baseline vWF measurements, there was significantly decreased vWF in Ga12 2/2 mice, which leads to the initial conclusion that basal vWF could be regulated by Ga12; the EC-Gaq 2/2 ; Ga11 2/2 mice were the same as control.
However, in both knockout mice, there was a significant decrease in the amount of vWF from lung perfusate after activation of PAR-1 receptors by the mimetic-peptide TFLLR with little to no response. This was a clear demarcation between the 2 G proteins, with Ga12 a component to basal vWF secretion and Gaq not involved with vWF secretion until after PAR-1 activation. The loss of vWF secretion in these mice was further demonstrated by increased blood loss after tail snip and reduced platelet thrombus formation. Taken together, the authors provide evidence at the whole-animal level for a role between GPCRs and vWF secretion.
To dissect the molecular mechanisms possibly governing these observations, the authors turned to cultured endothelial cells and a heterologous expression system. Using a genetic library of Ga12 mutants in which segments of the Ga12 sequence were replaced with Asn-Ala-Ala-Ile-Arg-Ser cassettes, they examined the ability of purified aSNAP to bind the Ga12 protein directly. They identified a unique sequence in Ga12 (amino acids 10-15) and produced a minigene construct against it, with the thought of inhibiting the Ga12-aSNAP interaction. When the construct was introduced into endothelial cells, it was able to significantly reduce the amount of vWF secreted after PAR-1 activation. When summed, the Ga12 activation in basal and stimulated conditions can regulate vWF secretion by direct interactions with aSNAP, as well as the classical Ga12 pathway after stimulated conditions; Gaq moving through its classical transduction pathway only participates in vWF secretion after stimulation (see figure) .
In a broader context related to endothelial cell biology, another key component of this article relates to the authors' discovery that the vWF secretion is tightly regulated by a series of proteins both in close proximity and with redundant functions. This observation is consistent with the current state of the field in Schematic of vWF secretion from endothelial cells under basal and stimulated conditions. Note the role of Ga12 in both basal and stimulated vWF secretion acting directly through aSNAP; however, Gaq11 only appears to be active on PAR-1 activation. See Figure 7 in the article by Rusu et al that begins on page 442. endothelial cell biology, where an accumulation of evidence appears to indicate discreet signaling microdomains that can regulate distinct physiological functions ranging from integrin function 6 to nitric oxide production 7 and calcium events. 8 Considering the balancing act that an endothelial cell must perform (respond to inflammatory stimuli/blood factors and regulate constriction and/or dilation), it is no wonder this cell is so clever with protein organization and use.
There is still much to do concerning mechanisms and triggers involved in WPB docking and vWF secretion. For example, where on the plasma membrane does the docking occur? It is likely that lipid raft accumulation clusters the components in particular areas of endothelial cells. In disease states with turbulent flow (eg, atherosclerosis), could that alter the dynamics of where the proteins are localized and/or function? Is there any secondary role for Ga13 in vWF secretion? Also, how does the endothelial cell confine the response to just WPB docking? Do localized calcium events prevent other physiological functions from occurring after activation of Ga? Pharmacologically, how can the Ga-initiated vWF secretion be targeted? This is an especially important question, considering that targeting a-SNAP could have several nonspecific effects (eg, neuronal function). The work described by Rusu et al provides the basis for starting to elucidate some of these exciting questions.
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